Building a brain in the gut: development of the enteric nervous system


The enteric nervous system (ENS), the intrinsic innervation of the gastrointestinal tract, is an essential component of the gut neuromusculature and controls many aspects of gut function, including coordinated muscular peristalsis. The ENS is entirely derived from neural crest cells (NCC) which undergo a number of key processes, including extensive migration into and along the gut, proliferation, and differentiation into enteric neurons and glia, during embryogenesis and fetal life. These mechanisms are under the molecular control of numerous signaling pathways, transcription factors, neurotrophic factors and extracellular matrix components. Failure in these processes and consequent abnormal ENS development can result in so-called enteric neuropathies, arguably the best characterized of which is the congenital disorder Hirschsprung disease (HSCR), or aganglionic megacolon. This review focuses on the molecular and genetic factors regulating ENS development from NCC, the clinical genetics of HSCR and its associated syndromes, and recent advances aimed at improving our understanding and treatment of enteric neuropathies.

Conflict of interest

The authors have no conflict of interest.
ENS contains many different types of neurons, including primary afferent neurons that sense chemical or mechanical stimuli in the lumen and then signal via ascending and descending interneurons to excitatory and inhibitory motoneurons that control effector cell function (4). The reflex circuits produced by these synaptically interconnected neurons are responsible for coordinating the major functions of the ENS, including the regulation of intestinal motility, absorption, secretion, and blood flow.

Congenital and acquired enteric neuropathies can lead to serious health consequences, typically manifesting with abnormal gut motor function (5, 6). For example, inflammatory enteric neuropathies, which can be caused by paraneoplastic, infectious, or immunemediated diseases, can lead to gastroparesis, intestinal pseudo-obstruction, or colonic inertia. Deficiencies of selective neurotransmitters have been described in esophageal achalasia and congenital hypertrophic pyloric stenosis, both associated with abnormal intestinal sphincter function. Mitochondrial dysfunction can lead to intestinal dysmotility from neuronal cell injury, as in mitochondrial neurogastrointestinal encephalopathy. Enteric ganglioneuromas, occurring in multiple endocrine neoplasia type 2B, are associated with severe colonic dysmotility (7).

The classic enteric neuropathy is Hirschsprung disease (HSCR), a congenital disease characterized by the absence of enteric ganglia along variable lengths of distal colon (8, 9). Congenital aganglionosis, which occurs in 1 in 5000 live-births, is limited to the rectosigmoid colon in 80% of cases, referred to as short-segment HSCR (S-HSCR), and most commonly presents with the failure of a newborn to pass meconium within 48 h of life, often with abdominal distension and vomiting. A contrast enema X-ray showing narrowing of the distal colorectum with dilation proximally supports the diagnosis of HSCR, and a rectal biopsy revealing the absence of enteric ganglia makes the definitive diagnosis. Treatment consists of surgical resection of the aganglionic segment and Anastomosis of normally ganglionated bowel to the anus.

This review focuses on the molecular and cellular factors regulating ENS morphogenesis, the clinical genetics of HSCR and its associated syndromes, and recent advances aimed at improving our understanding and treatment of enteric neuropathies.

Development of the ENS
The ENS is entirely derived from the neural crest, a transient structure that arises early in development.
during formation of the neural tube, the precursor of the brain and spinal cord. The progeny of the neural crest, neural crest cells (NCC), migrate extensively throughout the embryo, proliferate, and differentiate into a wide variety of cell types including melanocytes, craniofacial cartilage and bone, neurons and glia of the peripheral and ENS, and smooth muscle (10). Failure in key processes underlying NCC development can result in a number of wide ranging clinically important neural crest disorders (neurocristopathies) that affect pigmentation, alter craniofacial formation, result in deafness, give rise to tumors, or impact the innervation of the gut (i.e. HSCR) (11).

Studies in the 1950s and 1970s on chick embryos demonstrated that the vagal (hindbrain) region of the neural crest, adjacent to somites 1–7, gives rise to the majority of ENS cells along the entire length of the gut. In the last few decades, numerous aspects of ENS development have been extensively studied, with remarkable conservation of cell behavior and molecular control described in species such as fish, avians, mice and humans. In the mouse, the most widely studied animal model of ENS development, vagal NCC emerge from the neural tube around embryonic day 8.5 (E8.5), reach the foregut at E9–E9.5 (12, 13), and migrate rostrocaudally to colonize the entire length of the gut by E13.5–14 (14). In the human, this journey by vagal NCC along the gut begins at week 4 of gestation and is completed by approximately week 7 (15). In addition to this principal vagal NCC contribution to the gut, a second, more caudal region of the neuraxis, the sacral neural crest, also contributes a smaller number of cells that mainly colonize the terminal region of the mouse and avian hindgut (16, 17). Sacral neural crest-derived cells migrate rostrocaudally along the hindgut, opposite to the direction of migration of the vagal neural crest-derived cells. The neuronal subtypes and role(s) of sacral NCC remain unclear, and whether the sacral neural crest contributes to human ENS formation is still unknown.

In order to form a functional ENS along the entire length of the gut, vagal and sacral NCC must undergo a number of key processes including migration, survival, proliferation, neuronal and glial differentiation, and axon formation (Figure 1). Numerous transcription factors, signaling pathways, and neurotrophic factors have been shown to be involved in regulating each of these critical processes, a number of which are summarized in Table 1, elaborated upon below, and reviewed previously (18, 19). These advances in our understanding of ENS development have allowed a number of markers to be used to identify undifferentiated NCC prior to their entry into the gut (termed pre-enteric NCC), including the transcription factors Sox10 and Phox2b, the G protein-coupled receptor endothelin receptor B (EdnrB), the low-affinity nerve growth receptor p75, and the receptor tyrosine kinase Ret (Table 1).

Enteric NCC (ENCCs), as they are termed upon entering the gut, are undifferentiated at the wavefront of migration and express Sox10, Ret, p75, Phox2b, Ednrb and the transcriptional regulator Mash1. Behind the migratory wavefront, ENCCs are at different stages of maturation, with neuronal differentiation, which begins before glial differentiation, commencing shortly after they invade the foregut. This commitment to the neuronal lineage is associated with downregulation of Sox10 and p75, maintenance of Ret and Phox2b expression, and upregulation of pan-neuronal markers, including PGP9.5, neurofilament, neuronal class III β-tubulin (TuJ1), HuC and HuD. Although committed to a neuronal fate, these cells are still considered to be progenitors as they lack neuron-subtype-specific markers (e.g. NOS, VIP, NPY, SubP, ChAT) and remain mitotically active. To commit to the glial lineage, ENCCs maintain Sox10 and p75 expression, downregulate Ret, and upregulate B-FABP first and S100 and GFAP later in their differentiation (Table 1).

### Molecular mechanisms in ENS development

ENS development is a highly dynamic process in which ENCC migration, proliferation, and differentiation all occur simultaneously at different positions along the gut. While most cells at the migratory wavefront continue to proliferate and invade regions lacking ENCCs, those behind the wavefront establish themselves and begin to differentiate into neurons or glia, although some continue to proliferate to fill gaps created by the growing intestine. Several signaling pathways have essential roles in coordinating these processes and the timing and location of their expression is critical.

**Ret and Ednrb signaling: balancing cell proliferation and differentiation in the ENS**

Glia cell-derived neurotrophic factor (GDNF) is expressed in the mesoderm of the embryonic gut and activates a receptor complex on migrating ENCCs. This complex consists of the transmembrane receptor tyrosine kinase, Ret, and a co-receptor, Gdnf family receptor α1 (GFRα1) (20). Null mutations of Ret, Gdnf, or GFRα1 result in aganglionosis of the small and large intestine (21–24), and Gdnf haploinsufficiency leads to severe hypoganglionosis (25) (Table 2). At early stages, Ret signaling supports the survival of ENCCs, with its loss leading to significant apoptosis in the foregut (26). Ret is also strongly mitogenic (27–31), an essential function for expanding the pool of ENCCs so that sufficient numbers are available to colonize the entire GI tract. The proliferative effect of Gdnf-Ret signaling predominates during early stages when ENCCs are still migrating along the gut (27, 31), whereas at later developmental stages, Gdnf-Ret promotes neuronal differentiation (26–28). GDNF is also a potent chemoattractive factor for ENCCs, expressed most highly in the intestinal mesenchyme ahead of the wavefront and thereby possibly drawing them distally down the gut (31–33). A neurotrophic factor closely related to GDNF, neurturin, also activates the Ret receptor. Mouse mutations in this gene result in hypoganglionosis specifically affecting the myenteric plexus (34).
Table 1. Molecular markers expressed by NCC and their cellular derivatives at key stages of ENS development in the mouse [modified from (19)].

<table>
<thead>
<tr>
<th>Stage of development</th>
<th>Key cellular events</th>
<th>Cell types</th>
<th>Markers expressed by NCC and their progeny</th>
</tr>
</thead>
<tbody>
<tr>
<td>E8.5</td>
<td>Delamination from vagal region of neural tube</td>
<td>Vagal NCCs</td>
<td>Sox10/p75</td>
</tr>
<tr>
<td>E9.5</td>
<td>Invasion of the embryonic foregut by vagal progenitor cells</td>
<td>Pre-enteric NCCs</td>
<td>Sox10/p75 ± RET/Phox2b</td>
</tr>
<tr>
<td>E10.5</td>
<td>Rostrocaudal migration of progenitor cells</td>
<td>ENCCs (progenitor cells)</td>
<td>Sox10/p75/RET/Phox2b; EDNRB; Mash1</td>
</tr>
<tr>
<td></td>
<td>Proliferation of progenitor cells</td>
<td>Immature neurons</td>
<td>RET/Phox2b/PGP9.5/HuC-D/ TuJ1 ± Mash1/TH</td>
</tr>
<tr>
<td></td>
<td>Start of neuronal differentiation</td>
<td>Immature glial cells</td>
<td>Sox10/p75/B-FABP</td>
</tr>
<tr>
<td>E11.5</td>
<td>Rostrocaudal migration of progenitor cells</td>
<td>ENCCs (progenitor cells)</td>
<td>Sox10/p75/RET/Phox2b; EDNRB; Mash1</td>
</tr>
<tr>
<td></td>
<td>Proliferation of progenitor cells</td>
<td>Immature neurons</td>
<td>RET/Phox2b/PGP9.5/HuC-D/ TuJ1 ± Mash1/TH; ± NOS; ± Calb</td>
</tr>
<tr>
<td></td>
<td>Neuronal differentiation (appearance of first neurotransmitters)</td>
<td>Immature glial cells</td>
<td>Sox10/p75/B-FABP</td>
</tr>
<tr>
<td></td>
<td>Start of gial differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E13.5</td>
<td>Completion of rostrocaudal migration of vagal progenitor cells</td>
<td>Sacral NCCs</td>
<td>Sox10/p75 ± RET/Phox2b</td>
</tr>
<tr>
<td></td>
<td>Invasion of the embryonic hindgut and caudo-rostral migration of sacral progenitor cells</td>
<td>ENCCs (progenitor cells)</td>
<td>Sox10/p75/RET/Phox2b; EDNRB</td>
</tr>
<tr>
<td></td>
<td>Proliferation of progenitor cells</td>
<td>Immature neurons</td>
<td>RET/Phox2b/PGP9.5/HuC-D/ TuJ1 ± Mash1/TH; ± Calb; ± VIP; ± NPY</td>
</tr>
<tr>
<td></td>
<td>Neuronal differentiation</td>
<td>Immature glial cells</td>
<td>Sox10/p75/B-FABP</td>
</tr>
<tr>
<td></td>
<td>Gial differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P0 (to adult)</td>
<td>Proliferation of progenitor cells</td>
<td>ENCCs (progenitor cells)</td>
<td>Sox10/p75 ± RET/Phox2b</td>
</tr>
<tr>
<td></td>
<td>Differentiation of mature neuronal phenotypes</td>
<td>Neurons</td>
<td>RET/Phox2b/PGP9.5/HuC-D/ TuJ1 ± NOS; ± Calb; ± VIP; ± NPY; ± SubP; ± CGRP; ± 5HT; ± ChAT; ± Calret</td>
</tr>
<tr>
<td></td>
<td>Differentiation of mature glial phenotype/s</td>
<td>Glial cells</td>
<td>Sox10/p75/Phox2b/B-FABP/S100β/GFAP</td>
</tr>
<tr>
<td></td>
<td>Gangliogenesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Formation of functional neuronal circuits (i.e. onset of co-ordinated intestinal motility)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

E, embryonic day; ENCC, enteric neural crest cells; ENS, enteric nervous system; NCC, neural crest cells.

Another major signaling pathway in ENS development is endothelin-3 (ET3) – EDNRB. ET3 is a 21 amino acid peptide expressed in the gut mesoderm, while its G protein-coupled receptor, EDNRB, is present on the ENCC. Targeted mutation of either gene in mice, or of the endothelin converting enzyme-1 (ECE-1) that cleaves ET3 from its larger precursor, leads to aganglionosis of the distal colon and pigmentation defects due to deficient melanocytes (35–37). The primary role of EDNRB signaling is to inhibit the differentiation of ENCCs (28, 38, 39) and to keep them in a proliferative state (30, 39), thereby maintaining a pool of uncommitted progenitors. Whereas these undifferentiated ENCCs can continue migrating, once they differentiate into neurons they become post-mitotic and unable to migrate any farther, leading to the distal aganglionosis seen in ET3 and EDNRB mutant animals (40) (Table 2).

A critical determinant of normal ENS development is the size of the ENCC population available to colonize the gut. Experimentally reducing the size of the vagal neural crest in avians leads to distal intestinal aganglionosis (41–43). It has been shown that a critical density of cells at the wavefront is necessary to form the cellular strands that drive ENCC migration (44, 45). A low ENCC density delays their rate of migration, which may leave the cells unable to colonize a distal environment that has changed by the time they arrive (46, 47), thus coupling cell numbers, rate of migration, and maturation of the microenvironment. ENCC proliferation is thus critically important to drive their colonization, as shown by both experimental and mathematical modeling (48, 49). Balancing proliferation and differentiation are therefore vital to ENS development. Whereas ET3 and GDNF act synergistically to enhance ENCC proliferation (30), they have antagonistic roles with respect to ENCC differentiation and migration, with ET3 inhibiting both of these GDNF-mediated processes (28, 31, 38, 39). This coordinated activity is essential, particularly in the cecal region, where GDNF expression is strongest at the stage when ENCCs are arriving there (31, 33).
Table 2. Mouse models of intestinal aganglionosis and gut phenotypes in homozygous null and heterozygous mutants

<table>
<thead>
<tr>
<th>Gene</th>
<th>Homozygous phenotype</th>
<th>Heterozygous phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ret</td>
<td>AG of small and large intestine (21)</td>
<td>Normal (21)</td>
</tr>
<tr>
<td>Gdnf</td>
<td>AG of small and large intestine (22,23,24)</td>
<td>Hypoganglionosis (25)</td>
</tr>
<tr>
<td>Gfra1</td>
<td>AG of small and large intestine (107,108)</td>
<td>Normal (107)</td>
</tr>
<tr>
<td>Et3a</td>
<td>Distal colon AG (36)</td>
<td>Normal (36)</td>
</tr>
<tr>
<td>Ednrt2</td>
<td>Distal colon AG (35)</td>
<td>Hyperganglionosis in submucosal plexus (109)</td>
</tr>
<tr>
<td>Ece-1</td>
<td>Distal colon AG (37)</td>
<td>ND</td>
</tr>
<tr>
<td>Sox10</td>
<td>Total intestinal AG (50)</td>
<td>Distal colon AG (50,51,110)</td>
</tr>
<tr>
<td>b1-integrin</td>
<td>Distal colon AG (59)</td>
<td>ND</td>
</tr>
<tr>
<td>Phox2b</td>
<td>Total intestinal AG (56)</td>
<td>Normal</td>
</tr>
<tr>
<td>Mash1</td>
<td>AG of esophagus (111)</td>
<td>ND</td>
</tr>
<tr>
<td>Pax3</td>
<td>AG of small and large intestine (55)</td>
<td>Normal</td>
</tr>
<tr>
<td>Ihh</td>
<td>Patchy AG in small and large intestine (112)</td>
<td></td>
</tr>
</tbody>
</table>

AG, aganglionosis; ND, not done.

Additional signals involved in ENS formation

Haploinsufficiency of Sox10, a SRY-related HMG transcription factor expressed by undifferentiated ENCC progenitors, leads to distal colonic aganglionosis in mice (50, 51). Sox10 supports the survival of ENCC progenitor cells, with its loss leading to NCC apoptosis prior to their arrival in the foregut (52). Acting together with EdnrB, whose enhancer has SOX10-binding sites (53), Sox10 also acts by maintaining ENCCs in an undifferentiated state (54). Similar to ET3 signaling, Sox10 appears to promote maintenance of a pool of progenitor cells for ENS colonization. Sox10 has also been implicated in the activation of Ret transcription (55) and may influence ENS development via that pathway as well. Mice lacking Phox2B, a transcription factor expressed by ENCC progenitor cells (56), develop aganglionosis below the stomach, similar to the Ret knockout phenotype (Table 2). This may be explained by the finding that Phox2B is required for Ret expression (56).

NCC migration, survival, and proliferation rely not only on signaling molecules acting on their respective receptors, but also on the interactions between NCC and the extracellular matrix (57). The aganglionic colon of ET3 mutant mice is rich in laminin, which promotes enteric neurogenesis and may contribute to the premature differentiation and distal aganglionosis occurring in this model (58). Studies in EDNRB mutant mice suggest that the observed delay in ENCC migration results in ENCCs reaching the colon at a time when it has become non-permissive, possibly due to increased laminin expression in the more mature colon (46). ENCC-specific deletion of β1 integrin, which is expressed by ENCCs and required for their interaction with the extracellular matrix, leads to abnormal cellular adhesion, delayed migration, and distal aganglionosis (59) (Table 2). The migratory defect occurs specifically in the cecum/proximal hindgut and is thought to be due to a requirement for β1 integrin-mediated interactions between ENCCs with tenascin-C and fibronectin, which are both highly expressed in the mouse cecum when ENCCs arrive there (60). In avians, ENS formation requires the presence of endothelial cells, which ENCCs appear to use as a scaffold to guide their migration via a β1 integrin-dependent interaction between ENCCs and the endothelial cell basement membrane (61).

Recently, retinoic acid was shown to be required for ENS development, supporting a non-genetic factor as a possible contributor to the pathogenesis of HSCR. Mice depleted of Vitamin A show colorectal aganglionosis due to impaired lamellipodia formation and reduced ENCC migration in response to GDNF (62).

Hirschsprung disease

HSCR and the challenge of colonizing the distal bowel

Why the distal end of the colon is particularly susceptible to aganglionosis, as occurs in HSCR, is not entirely clear. Reduction of Ret dosage to one third of normal levels leads to colonic aganglionosis (63). Other mouse models also display aganglionosis limited to the colorectal region, including mice expressing only the Ret51 allele (64), Sox10 heterozygotes (51), and targeted mutants of the ET3-EdnrB pathway (35, 36). As the majority of ENS colonization occurs rostrocaudally, distal aganglionosis may simply reflect the distance ENCCs need to migrate to reach the end of the gut. Given the importance of ENCC proliferation for generating an adequate pool of progenitor cells to populate the intestine, inadequate cell numbers could account for the distal aganglionosis. However, conditional inactivation of Ret in late development, after ENS migration has completed, leads to enteric neuronal cell death specifically in the colon (63), suggesting that certain aspects of ENCC development may be unique to the distal gut and that other etiologies may account for the HSCR phenotype.

Genes involved in the development of HSCR disease

HSCR is considered an inherited disease which can be transmitted in a Mendelian way, both as a dominant trait and as a recessive trait. The majority of cases are probably polygenic/multifactorial with differences
in sex ratio, with a male predominance in S-HSCR (4:1), incomplete penetrance and variable expression. Associations with a large number of syndromes and congenital malformations have been observed (65). Linkage analyses of multiplex HSCR families revealed that the \textit{RET} gene, located at 10q11.2, is the major risk factor as almost all HSCR families showed linkage with \textit{RET} (66, 67). Coding sequence mutations in \textit{RET} are responsible for a dominant form of HSCR (with incomplete penetrance) and coding and splice site mutations have been identified in up to 50% of familial cases and 15–35% of sporadic cases (68). The mutations are scattered throughout the \textit{RET}-coding sequence, including large and micro-deletions and a variety of point mutations. \textit{RET} mutations associated with HSCR are believed to cause a loss of function (haploinsufficiency) (69–71). However, \textit{RET} mutations on their own might not result in aganglionosis, as the penetrance of the \textit{RET} mutations (in general) is 72% in males and 51% in females. In addition to \textit{RET}, mutations have been found in 11 other genes (Table 3). Mutations in these genes, namely \textit{EDNRB} (72), \textit{EDN3} (73, 74), \textit{ECE1} (75), \textit{GDNF} (76, 77), \textit{NTN} (78), \textit{SOX10} (79), \textit{PHOX2B} (80), \textit{KIAA1279/KBP} (81), \textit{ZFHX1B} (82, 83), \textit{TTF1} (84), do not account for more than 20% of the cases, supporting genetic heterogeneity for this disorder.

Genes involved in syndromic HSCR

Mutations in many of the genes are found in syndromic HSCR cases (Table 3). Mutations in \textit{EDNRB}, \textit{EDN3} and \textit{SOX10} were identified in a patient with Shah–Waardenburg syndrome (WS4), which is characterized by congenital hearing loss, pigmented abnormalities of the hair, skin and eyes, and HSCR disease (79, 86). Mutations in \textit{PHOX2B} have been identified in patients with congenital central hypoventilation syndrome (CCHS) and HSCR disease. CCHS is a rare disorder characterized by impairment of autonomic control of spontaneous respiration in the absence of other lung or cardiac disease (80). The coexistence of CCHS and HSCR is known as Haddad syndrome. Mutations in \textit{ZFHX1B} have been identified in patients with Mowat–Wilson syndrome, an autosomal dominant disorder characterized by mental retardation, epilepsy, delayed motor development, and HSCR disease (82). Mutations in \textit{KIAA1279} [now called kinesin-binding protein (KBP)] have been identified in patients with Goldberg–Shprintzen syndrome, a rare autosomal recessive disorder characterized by HSCR, microcephaly, mental retardation, and polymicrogyria (81). A mutation in \textit{ECE1} was identified in a single patient with craniofacial and cardiac defects (75). Finally, specific mutations in \textit{RET} have been found in patients with HSCR in combination with the cancer syndrome multiple endocrine neoplasia type 2A (MEN2A) or familial medullary thyroid carcinoma (FMTC) (87). Besides mutations in these genes, chromosomal abnormalities are observed in 12% of all syndromic HSCR cases. Trisomy 21 (Down syndrome), which occurs in up to 10% of children with HSCR, is the most frequent, accounting for >90% of all known chromosomal defects associated with this disease (65).

Non-coding \textit{RET} variants

As mentioned above, \textit{RET}-coding mutations have been identified in 50% of familial cases. However, regardless of the \textit{RET}-coding mutation status, almost all familial cases are linked to the \textit{RET} locus (66, 88). This suggests that non-coding \textit{RET} mutations must play a major role in the remaining cases. This idea was corroborated in association studies on sporadic (simplex) cases with and without \textit{RET}-coding mutations, performed on several Caucasian populations and an Asian population. These studies revealed a strong association between a certain haplotype (covering 27 kb in total) and the disease. This haplotype starts 4 kb upstream of the \textit{RET} transcription start site, going all the way to the beginning of exon 2. This haplotype is present in 56–62% of patients, but only 20% of controls, in the Caucasian population. In the Chinese patient population, the frequency of this haplotype was 85%, and 40% in controls. This finding might partially explain the higher incidence of HSCR in Asians compared to Caucasians. Several groups have

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|}
\hline
\textbf{Gene symbol} & \textbf{Position} & \textbf{Inheritance} & \textbf{Phenotype} \\
\hline
\textit{RET} & 10q11.2 & Dominant, incomplete penetrance & Non-syndromic/MEN2A \\
\textit{GDNF} & 5p13 & Non-Mendelian & Non-syndromic \\
\textit{NTN} & 19p13 & Non-Mendelian & Non-syndromic \\
\textit{EDNRB} & 13q22 & Recessive Dominant (de novo in 80%) & Shah–Waardenburg Non-syndromic \\
\textit{EDN3} & 20q13 & Recessive Dominant, incomplete penetrance & Shah–Waardenburg Non-syndromic \\
\textit{PHOX2B} & 4p12 & Dominant (de novo in 90%) & Haddad syndrome (CCHS) \\
\textit{SOX10} & 22q13 & Dominant (de novo in 75%) & Shah–Waardenburg \\
\textit{ECE1} & 1p36 & Dominant (de novo) & Congenital heart formation \\
\textit{ZFHX1B (SIP1)} & 2q22 & Dominant (de novo) & Mowat–Wilson \\
\textit{KIAA1279 (KBP)} & 10q22.1 & Recessive & Goldberg–Shprintzen \\
\textit{TTF1 (TITF1)} & 14q13 & – & Non-syndromic \\
\textit{NRG1} & 8p21 & – & Non-syndromic \\
\hline
\end{tabular}
\caption{Hirschsprung disease associated genes and their clinical features (modified from (99))}
\end{table}

\textit{CCHS}, congenital central hypoventilation syndrome.
focused their studies on fine-mapping the associated region to identify the location of the causative variant (84, 89–96).

Susceptible HSCR loci

Investigators are actively searching for additional susceptibility loci, with or without an associated RET mutation. Linkage studies on multiplex HSCR families identified a new locus at 9q31 in families linked to RET but without a RET-coding mutation (88). Sibpair analysis in nuclear families with S-HSCR resulted in significant allele sharing with markers on 10q11 (RET), and two new loci on 19q12 and on 3p21, respectively (66). A genome-wide scan on 43 Mennonite trios, all belonging to the same large kindred, resulted in three loci, two of which were known loci (13q22.3-q31.1, EDNRB; 10q11.21, RET) and one new locus on 16q23.3 (97). Studying a large multigenerational Dutch family with an isolated HSCR phenotype resulted in the identification of a new susceptibility locus on 4q31-32 (98). Finally, a genome-wide association study on Chinese patients identified NRG1 as a susceptibility locus for HSCR (85).

Genetic testing for HSCR – what and who to test?

Current knowledge on the genetic background of HSCR has brought forward, for the patient, several important new insights. The most significant is perhaps the fact that a few percent (up to 3%) of non-syndromic HSCR patients have a RET mutation that predisposes them not only for HSCR but also for the cancer syndrome MEN2A or FMTC. As the detection of such a RET mutation has profound clinical consequences for the patients and his or her family it is recommended that all non-syndromic HSCR patients are screened for these specific mutations (87, 99). This testing should only be offered in combination with genetic counseling. Genetic counseling is also recommended in all syndromic HSCR cases. Depending on the disease phenotype one could decide to screen for specific gene(s). Another reason for molecular testing of RET could be to give more accurate estimates for recurrence risks to parents of a non-syndromic HSCR patient. For instance, the finding of a pathogenic RET mutation in a male proband with L-HSCR and the exclusion of this mutation in the parents may allow lowering of the recurrence risk of 13–17% to less than 1%, taking into account the theoretical possibility of a mosaic germ line mutation in one of the parents (100).

Future directions

Better understanding of, and therapies for, congenital diseases affecting the ENS

After over two decades of intense investigations, our understanding of the developmental biology, genetics and etiology of HSCR has significantly advanced. However, the defining characteristics of a number of other enteric neuropathies are still lacking (101, 102). This is partly due to the relatively rare incidence of these diseases, the lack of well defined neuropathological features, and the scarcity of animal models in which specific gut motility defects can be investigated. Future work may be directed towards: (i) identifying phenotype/genotype associations within well-defined patient groupings (which may require the establishment of international consortia to accumulate a ‘critical mass’ of patients and tissues for analysis); (ii) utilizing evolving genetic technologies to identify candidate genes for enteric neuropathies; (iii) using animal models including zebrafish and mice to investigate potential mechanisms underlying enteric neuropathies, including aberrant development of neuronal subtypes, inappropriate neuronal wiring and network formation, and (iv) developing novel therapies for congenital diseases affecting the ENS (Fig. 2).

For this latter point, although gut motility disorders represent relatively rare but clinically challenging conditions with little in the way of definitive cures, a number of groups worldwide are currently focusing on the possibility of utilizing stem cells to replace or restore missing or defective ENS cells, particularly with therapy for HSCR in mind. Typical investigative approaches include isolation and propagation of stem cells from various sources (including the gut or CNS, as

---

*Fig. 2. Flow diagram showing potential experimental approaches for gaining insight to the molecular mechanisms underlying enteric neuropathies, and development of novel therapies for their treatment.*

---

1. e.g. hypoganglionosis, neuronal intranuclear inclusion disease, ganglionitis, degenerative neuropathy, diffuse gangliononeuromatosis, neuronal dysplasia.
well as iPS and embryonic stem cells), transplantation of stem cells into mouse or other models of gut aganglionosis, and assessment of gut function following transplantation (for reviews see (103–106)). The next challenges in this field will be to progress from animal models to the isolation and characterization of stem cells from human sources, and move to ‘first in man’ studies whereby stem cell delivery methods, safety and efficacy can be assessed. With these steps in mind, advances in the understanding and treatment of ENS disorders will continue to advance at a rapid pace.

Acknowledgement

A. M. G. is supported by NIH R01DK080914.

References


